Olesia Kalmukova

Dr. Olesia Kalmukova

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
MTMax Temnik
Max Temnik
SGSergey Gurin
Sergey Gurin
ABAlexandr Balakin
Alexandr Balakin
RBRoman Byshovets
Roman Byshovets
OKOlesia Kalmukova
Olesia Kalmukova
OSOlexiy Savchuk
Olexiy Savchuk
Zinc is a critical micronutrient that plays multifaceted roles in oxidative stress management, lipid metabolism, pancreatic function, and liver health, which are all closely interconnected with obesity. Maintaining adequate zinc levels is essential for overall metabolic health and proper functioning of these vital systems. The investigational new drug complex of zinc-64 aspartate (KLS-1 or 64Zn-aspartate) was evaluated in this study as a pharmaceutical agent targeting oxidative stress and lipid metabolism using rodent model of obesity. KLS-1 is the isotopically modified zinc aspartate in which stable (non-radioactive) 64Zn atoms were enriched to exceed 99% atomic fraction of total zinc, as compared to natural isotopic ratio of 64Zn of 48.6%. In this paper, we discuss our findings and the effects rendered by KLS-1 on lipid metabolism, pancreas and liver function. This study was conducted on outbred rats, which were divided into four experimental groups: 1) the control group consuming standard food (3.81 kcal/g), 2) the obese group consuming a high-calorie diet (5.35 kcal/g), 3) the obese group consuming a high-calorie diet (5.35 kcal/g) treated with intragastric administration of 64Zn- aspartate at a dose of 4.5 mg per animal during 6 weeks (the obese rats), 4) the group consuming standard food diet (3.81 kcal/g) with 64Zn- aspartate form administration. The obese rats treated with 64Zn-64 stable isotope demonstrated decreased area of the hepatocytes, insulin and glucose levels in serum; increased catalase and superoxide dismutase activity, and area of pancreatic islets in comparison with the obese group. The study shows that 64Zn-aspartate is effective as a therapeutic agent for obesity management, significantly reducing body mass, improving histopathological changes in the pancreas and liver and normalizing oxidative stress in high-calorie diet animal models. These findings suggest that 64Zn- aspartate may be a promising monotherapy or adjunct treatment for obesity, offering benefits in weight reduction, organ protection, and antioxidant balance.


3 December 2025 in Scientific Reports
Verified
Journal Article
Open access
MTMax Temnik
Max Temnik
SGSergey Gurin
Sergey Gurin
LMLeonid Magidenko
Leonid Magidenko
ABAlexandr Balakin
Alexandr Balakin
RBRoman Byshovets
Roman Byshovets
OSOlexiy Savchuk
Olexiy Savchuk
Obesity-induced metabolic syndrome is characterized by chronic inflammation, hormonal imbalance, and altered neurotransmitter metabolism. Zinc plays a critical role in immune regulation and energy balance; however, the effects of isotopically modified chelate complexes in metabolic functions remain unexplored. This study investigated the therapeutic effects of isotopically enriched Zn64 Aspartate in a rat model of diet-induced obesity, focusing on inflammation, adipokine secretion, and tryptophan metabolism across serum, brain, duodenum, the pancreas, and adipose tissues. Male Wistar rats were fed a high-fat diet to induce obesity and treated with Zn64 Aspartate. Proinflammatory and anti-inflammatory cytokine levels, resistin, ghrelin, serotonin, tryptophan concentrations, and enzymatic activities of tryptophan hydroxylase (TPH), indoleamine 2,3-dioxygenase (IDO), and monoamine oxidase (MAO) were analyzed. Zn64 Aspartate significantly reduced pro-inflammatory cytokines and resistin levels while normalizing ghrelin. It enhanced serotonin levels and modulated TPH, IDO, and MAO activities in a tissue-specific manner, favoring serotonergic over kynurenine pathway metabolism. A decrease in pancreatic fibrosis, glycogen content, and an increase in the number of insulin-positive β-cells were observed in obese rats treated with Zn64 Aspartate, compared with the obese group. Conclusively, Zn64 Aspartate shows promise as a metabolic modulator by attenuating inflammation and restoring neuroendocrine balance in obesity. Further studies are warranted to validate its therapeutic potential.

1 January 2022 in Food Technology and Biotechnology
Verified
Journal Article
Open access
OKOlesia Kalmukova
Olesia Kalmukova
NRNataliia Raksha
Nataliia Raksha
TVTetiana Vovk
Tetiana Vovk
THTetiana Halenova
Tetiana Halenova
MDMykola Dzerzhynsky
Mykola Dzerzhynsky
LOLudmila Ostapchenko
Ludmila Ostapchenko
Research background. Despite clearly recognized links between increased body mass and increased risk for various pathological conditions, therapeutic options to treat obesity are still very limited. The aim of the present study is to explore the effect of low-molecular-mass collagen fragments obtained from the scales of Antarctic wild marine fish on rats’ visceral and subcutaneous white adipose tissue in a high-calorie diet-induced obesity model. Experimental approach. The study was conducted on outbred rats, which were divided into 3 experimental groups: (i) control, consuming standard food (3.81 kcal/g), (ii) obese group, consuming a high-calorie diet (5.35 kcal/g), and (iii) obese group, consuming a high-calorie diet (5.35 kcal/g) with intragastric administration of low-molecular-mass collagen fragments (at a dose 1 g/kg of body mass during 6 weeks). Low–molecular-mass collagen fragments were obtained by a procedure that included collagen extraction from fish scales and enzymatic hydrolysis with pepsin. Apart from hematoxylin and eosin staining, fibrosis level was assessed by histochemical Van Gieson’s trichrome picrofuchsin staining, and mast cells were analysed by toluidine blue O staining. Results and conclusions. Group treated with low-molecular-mass fragments of collagen exhibited decreased rate of mass gain, relative mass, area occupied by collagen fibre of both visceral and subcutaneous adipose tissue, and cross-sectional area of both visceral and subcutaneous adipocytes. Treatment with low-molecular-mass fragments of collagen reduced the infiltration of immune cells, number of mast cells and their redistribution back to the septa. This was also accompanied by a decreased number of the crown-like structures formed by the immune cells, which are markers of chronic inflammation that accompanies obesity. Novelty and scientific contribution. This is the first study that reports the anti-obesity effect of low-molecular-mass fragments produced as a result of controlled hydrolysis of collagen from the scales of Antarctic wild marine fish in the in vivo model. Another novelty of this work is the observation that the tested collagen fragments not only reduce the body mass, but also improve the morphological and inflammatory parameters (decrease in the number of crown-like structures, immune cell infiltration, fibrosis and mast cells). Altogether, our work suggests that low-molecular-mass collagen fragments are a promising candidate for amelioration of some comorbidities linked to obesity.

31 May 2016 in Cell and Organ Transplantology
Verified
Journal Article
Open access
PDF file
HSH. Svitina
H. Svitina
OKOlesia Kalmukova
Olesia Kalmukova
DSD. Shelest
D. Shelest
OSO. Skachkova
O. Skachkova
LGL. Garmanchuk
L. Garmanchuk
VSV. Shablii
V. Shablii
We describe the state of the immune system at the late stage of 1,2-dimethylhydrazine (DMH)-induced colon cancer and after administration of placenta-derived multipotent cells (PDMCs). The spleen and thymus indices did not differ among the groups of intact and DMH-treated rats and were not affected by the administration of placenta-derived multipotent cells following the DMH treatment. Moreover, no difference in spontaneous or stimulated phagocytic activity of peritoneal macrophages was observed between healthy rats or the animals with DMH-induced colon cancer (with or without the administration of PDMCs). However, the proliferation of the T cells in the spleen was lower in rats with colon cancer regardless of the administration of PDMCs. Similarly, no changes were observed in the cell cycle distribution of proliferating spleen cells after stimulation by lipopolysaccharide.Conclusion. Our data demonstrate the absence of the active reaction by peritoneal macrophages and spleen cells to a colon cancer at mid/late stage. Additionally, the administration of PDMCs does not result in a measurable anti-tumor immune response.

31 May 2018 in Cell and Organ Transplantology
Verified
Journal Article
Open access
OKOlesia Kalmukova
Olesia Kalmukova
MDM. Dzerzhinsky
M. Dzerzhinsky